News
Leap expands specialty infusion network with WeInfuse collaboration
Leap is expanding its employer specialty infusion network through a new collaboration with WeInfuse, the platform powering more than 1,400 independent infusion providers nationwide. The collaboration opens Leap’s Transparency Network to thousands of additional independent infusion centers, making Leap one of the largest specialty infusion networks available to self-funded employer health plans.
Participating WeInfuse providers, including ambulatory infusion centers, infusion suites, and home and specialty pharmacies, can now accept Leap-coordinated referrals through the systems they already use. Leap sources each therapy at true acquisition cost, with no buy-and-bill markup, while the site is paid a flat fee to administer it. The result is more options for patients to get convenient care close to home, lower total specialty infusion costs for employers and health plans, and a new source of patient volume for independent providers.
More insights
Infusion vs. injection: Breaking down the basics of these two specialty therapies
In 1995, there were about 30 specialty drugs on the market. Today, there are nearly 1,000, and rough...
Let's blow up the buy-and-bill drug model: How it works and what it costs employers
Twice a year, a member with multiple sclerosis (MS) sits down for an Ocrevus infusion. The drug is t...
The real cost of MS infusion therapy and how a better member experience can bring down costs
For two years, Maria drove two hours each way for her multiple sclerosis (MS) treatment. Every appoi...
The emerging oncology biosimilars market and how employers can prepare.
A member who starts Keytruda today will likely organize the next two years of their life around it. ...
Is home infusion safe for immunoglobulin therapy? What patients should know
Whether you've just been prescribed immunoglobulin (Ig) therapy, or you've been getting it at a clin...
The market is moving faster than most infusion strategies can keep up with
Hospital systems have been acquiring independent physician practices at a rapid pace for close to tw...
The $400K signal: What six months of Leap data says about the specialty drug trend
An employer offering a self-funded health plan came to Leap facing double-digit specialty trend, dri...
5 steps to implement a specialty infusion therapy program employees will actually use
Choosing the right vendor helps you understand the savings that are possible. But the right implemen...
What cancer patients can expect from oncology infusion and injection therapies
When chemotherapy ends for an oncology patient, the nausea and hair loss may ease. But a new phase o...
Bringing relief for Luka: From hospital stays to at-home infusion care
Luka is a child managing pediatric Crohn's disease. His care team prescribed Remicade, an infusion t...